AIDS:
Views on the Administration's Fiscal Year 1989 Public Health Service Budget
HRD-88-104BR: Published: Jun 2, 1988. Publicly Released: Jul 8, 1988.
Additional Materials:
- Full Report:
Contact:
In response to a congressional request, GAO reviewed the Public Health Service's (PHS) proposed fiscal year (FY) 1989 budget for Acquired Immunodeficiency Syndrome (AIDS) programs, focusing on the: (1) adequacy of the proposed budget; and (2) appropriateness of the proposed allocation of funds among various activities.
GAO noted that the proposed PHS budget included: (1) $588 million for biomedical research for a vaccine, cure, or improved treatment; (2) $400 million for public health control measures to educate the public; (3) $229 million for epidemiological studies and surveillance to understand and track the spread of AIDS; and (4) $68 million to provide health services to AIDS patients and substance abuse treatment for intravenous drug users. GAO found that the experts it interviewed: (1) believed that Congress should appropriate more funds for public health services in FY 1989; (2) proposed funding increases over the administration's $1.3 billion budget request ranging from $1.5 billion to $2.3 billion; and (3) believed that Congress should authorize more funds for controlling human immunodeficiency virus infection among intravenous drug users, educating high-risk groups, and providing patient care. GAO also found that: (1) state and local officials indicated that budget constraints could limit their biomedical research resources; (2) AIDS experts and federal officials believed that PHS staff shortages could adversely affect AIDS program management; and (3) AIDS experts believed that more effort should be devoted to health services research on cost effective methods for financing and delivering care.
Mar 3, 2021
-
Drug Safety:
FDA's Future Inspection Plans Need to Address Issues Presented by COVID-19 BacklogGAO-21-409T: Published: Mar 4, 2021. Publicly Released: Mar 3, 2021.
Mar 1, 2021
-
Medicare Part B:
Payments and Use for Selected New, High-Cost DrugsGAO-21-252: Published: Mar 1, 2021. Publicly Released: Mar 1, 2021.
Feb 24, 2021
-
Covid-19:
Key Insights from GAO's Oversight of the Federal Public Health ResponseGAO-21-396T: Published: Feb 24, 2021. Publicly Released: Feb 24, 2021.
Feb 17, 2021
Feb 11, 2021
-
Operation Warp Speed:
Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing ChallengesGAO-21-319: Published: Feb 11, 2021. Publicly Released: Feb 11, 2021.
Feb 5, 2021
-
DOD Health Care:
DOD Should Monitor Implementation of Its Clinical Practice GuidelinesGAO-21-237: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
Medicaid:
CMS Needs to Implement Risk-Based Oversight of Puerto Rico's Procurement ProcessGAO-21-229: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
VA Health Care:
Community Living Centers Were Commonly Cited for Infection Control Deficiencies Prior to the COVID-19 PandemicGAO-21-195R: Published: Jan 6, 2021. Publicly Released: Feb 5, 2021.
Jan 28, 2021
-
COVID-19:
Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal AttentionGAO-21-265: Published: Jan 28, 2021. Publicly Released: Jan 28, 2021.
Jan 21, 2021
-
Rural Hospital Closures:
Affected Residents Had Reduced Access to Health Care ServicesGAO-21-93: Published: Dec 22, 2020. Publicly Released: Jan 21, 2021.
Looking for more? Browse all our products here